Targeting ALT: The role of alternative lengthening of telomeres in pathogenesis and prevention of cancer

Cancer Treatment Reviews

Volumn 33, Issue 8, 2007, Pages 704-709

  Bollmann, F Mathias ^a  

^a ASKLEPIOS KLINIK ALTONA   (Germany)

Author keywords

ALT; Cancer; Crisis; Recombination; Senescence; Telomere; Tumor

Indexed keywords

TELOMERASE;

CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CELL DIVISION; DRUG TARGETING; GENE; HUMAN; NONHUMAN; REVIEW; TELOMERE;

ANIMALS; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE; TELOMERE-BINDING PROTEINS;

EID: 36048962744     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.08.006     Document Type: Review

References (63)

1. Olovnikov A.M. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 41 1 (1973) 181-190
2. Wright W.E., and Shay J.W. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 27 4 (1992) 383-389
3. Henson J.D., Neumann A.A., Yeager T.R., and Reddel R.R. Alternative lengthening of telomeres in mammalian cells. Oncogene 21 (2002) 598-610
4. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol 200; 19(3):114-20.
5. de Grey A.D.N.J., Campbell F.C., Dokal I., Fairbairn L.J., Graham G.J., Jahoda C.A.B., et al. Total deletion of in vivo telomere elongation capacity: an ambitious but possibly ultimate cure for all age-related human cancers. Ann NY Acad Sci 1019 (2004) 147-170
6. Bryan T.M., and Reddel R.R. Telomere dynamics and telomerase activity in in vitro immortalised human cells. Eur J Cancer 33 5 (1997) 767-773
7. Perrem K., Bryan T.M., Englezou A., Hackl T., Moy E.A., and Reddel R.R. Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids. Oncogene 18 (1999) 3383-3390
8. Grobelny J.V., Kulp-McEliece M., and Broccoli D. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway. Human Mol Gen 10 18 (2001) 1953-1961
9. Cerone M.A., Londono-Vallejo J.A., and Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Human Mol Gen 10 18 (2001) 1945-1952
10. Perrem K., Colgin L.M., Neumann A.A., Yeager T.R., and Reddel R.R. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 Cells. Mol Cell Biol 21 12 (2001) 3862-3875
11. Yeager T.R., Neumann A.A., Englezou A., Huschtscha L.I., Noble J.R., and Reddel R.R. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59 (1999) 4175-4179
12. Nabetani A., Yokoyama O., and Ishikawa F. Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body. J Biol Chem 279 24 (2004) 25849-25857
13. Grobelny J.V., Godwin A.K., and Broccoli D. ALT-associated PML bodies are present in viable cells and are enriched incells in the G2/M phase of the cell cycle. J Cell Sci 113 (2000) 4577-4585
14. Fasching C.L., Bower K., and Reddel R.R. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res 65 (2005) 2722-2729
15. Bechter O.E., Shay J.W., and Wright W.E. The frequency of homologous recombination in human ALT cells. Cell Cycle 3 5 (2004) 547-549
16. Bailey S.M., Brenneman M.A., and Goodwin E.H. Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells. Nucleic Acids Res 32 12 (2004) 3743-3751
17. Dunham M.A., Neumann A.A., Fasching C.L., and Reddel R.R. Telomere maintenance by recombination in human cells. Nature Gen 26 (2000) 447-450
18. Bechter O.E., Zou Y., Shay J.W., and Wright W.E. Homologous recombination in human telomerase-positive and ALT cells occurs with the same frequency. EMBO Rep 4 12 (2003) 1138-1143
19. Londono-Vallejo J.A., Der-Sarkissian H., Cazes L., Bacchetti S., and Reddel R.R. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res 64 (2004) 2324-2327
20. Bechter O.E., Zou Y., Walker W., Wright W.E., and Shay J.W. Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition. Cancer Res 64 (2004) 3444-3451
21. Jiang W.Q., Zhong Z.H., Henson J.D., and Reddel R.R. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene (2005) Advance Online Publication 5 February
22. Stavropoulos D.J., Bradshaw P.S., Li X., Pasic I., Truong K., Ikura M., et al. The Bloom syndrome helicase BLM interacts with TRF2 in ALT cells and promotes telomeric DNA synthesis. Human Mol Gen 11 25 (2002) 3135-3144
23. Lillard-Wetherell K., Machwe A., Langland G.T., Combs K.A., Behbehani G.K., Schonberg S.A., et al. Association and regulation of the BLM helicase by the telomere proteins TRF1 and TRF2. Human Mol Gen 13 17 (2004) 1919-1932
24. Opresko P.L., Otterlei M., Graakjaer J., Bruheim P., Dawut L., Kolvraa S., et al. The Werner syndrome helicase and exonuclease cooperate to resolve telomeric D loops in a manner regulated by TRF1 and TRF2. Mol Cell 14 6 (2004) 763-774
25. Celli G.B., Denchi E.L., and de Lange T. Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination. Nat Cell Biol 8 (2006) 855-890
26. Tanaka H., Mendonca M.S., Bradshaw P.S., Hoelz D.J., Malkas L.H., Meyn M.S., et al. DNA damage-induced phosphorylation of the human telomere-associated protein TRF2. Proc Natl Acad Sci USA 102 43 (2005) 15539-15544
27. Muntoni A., and Reddel R.R. The first molecular details of ALT in human tumor cells. Human Mol Gen 14 2 (2005) 191-196
28. Martens U.M., Chavez E.A., Poon S.S., Schmoor C., and Lansdorp P.M. Accumulation of short telomeres in human fibroblasts prior to replicative senescence. Exp Cell Res 256 (2000) 291-299
29. Natarajan S., Groff-Vindman C., and McEachern M.J. Factors influencing the recombinational expansion and spread of telomeric tandem arrays in Kluyveromyces lactis. Eukaryot Cell 2 5 (2003) 1115-1127
30. Tomaska L., Nosek J., Makhov A.M., Pastorakova A., and Griffith J.D. Extragenomic double-stranded DNA circles in yeast with linear mitochondrial genomes: potential involvement in telomere maintenance. Nucleic Acids Res 28 22 (2000) 4479-4487
31. Compton S.A., Choi J.H., Cesare A.J., Ozgur S., and Griffith J.D. Xrcc3 and Nbs1 are required for the production of extrachromosomal telomeric circles in human alternative lengthening of telomere cells. Cancer Res 67 4 (2007) 1513-1519
32. Wang R.C., Smogorzewska A., and de Lange T. Homologous recombination generates t-loop-sized deletions at human telomeres. Cell 119 3 (2004) 355-368
33. Ibanez de Caceres I., Frolova N., Varkonyi R.J., Dulaimi E., Meropol N.J., Broccoli D., et al. Telomerase is frequently activated in tumors with microsatellite instability. Cancer Biol Ther 3 3 (2004) 289-292
34. Scheel C., and Poremba C. Telomere lengthening in telomerase-negative cells: the ends are coming together. Virchows Arch 440 (2002) 573-582
35. Hakin-Smith V., Jellinek D.A., Levy D., Carroll T., Teo M., Timperley W.R., et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361 9360 (2003) 836-838
36. Ulaner G.A., Huang H.Y., Otero J., Zhao Z., Ben-Porat L., Satagopan J.M., et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63 (2003) 1759-1763
37. Sharpless N.E., and DePinho R.A. p53. Good cop/bad cop. Cell 110 1 (2002) 9-12
38. Razak Z.R.A., Varkonyi R.J., Kulp-McEliece M., Caslini C., Testa J.R., Murphy M.E., et al. p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance. Mol Cell Biol 24 13 (2004) 5967-5977
39. Chen Y.J., Hakin-Smith V., Teo M., Xinarianos G.E., Jellinek D.A., Carroll T., et al. Association of mutant TP53 with ALT and favorable prognosis in glioma. Cancer Res 66 13 (2006) 6473-6476
40. Sood A.K., Coffin J., Jabbari S., Buller R.E., Hendrix M.J.C., and Klingelhutz A. p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. Cancer Biol Ther 1 5 (2002) 511-517
41. Bossi G., and Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 29 3 (2007) 272-284
42. Mai S., and Garini Y. The significance of telomeric aggregates in the interphase nuclei of tumor cells. J Cell Biochem 97 (2006) 904-915
43. Maser R.S., and DePinho R.A. Connecting chromosomes, crisis and cancer. Science 297 5581 (2002) 565-569
44. Sharpless N.E., and De Pinho R.A. Telomeres, stem cells, senescence, and cancer. J Clin Invest 113 2 (2004) 160-168
45. Greenberg R.A., Chin L., Femino A., Lee K.H., Gottlieb G.J., Singer R.H., et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(Δ2/3) cancer-prone mouse. Cell 14 (1999) 515-525
46. Rudolph K.L., Chang S., Lee H.W., Blasco M., Gottlieb G.J., Greider C.W., et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96 (2001) 701-712
47. Artandi S.E., Chang S., Lee S.L., Alson S., Gottlieb G.J., Chin L., et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406 (2000) 641-645
48. O'Hagan R.C., Chang S., Maser R.S., Mohan R., Artandi S.E., Chin L., et al. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2 2 (2002) 149-155
49. Seger R.Y., Garcia-Cao M., Piccinin S., Cunsolo C.L., Doglioni C., Blasco M.A., et al. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2 5 (2002) 401-413
50. Farazi P.A., Glickman J., Jiang S., Yu A., Rudolph K.L., and DePinho R.A. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 63 (2003) 5021-5027
51. Chang S., Khoo C.M., Naylor M.L., Maser R.S., and DePinho R.A. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Develop 17 1 (2003) 88-100
52. Gupta J., Han L.P., Wang P., Gallie B.L., and Bacchetti S. Development of retinoblastoma in the absence of telomerase activity. J Natl Cancer Inst 88 16 (1996) 1152-1157
53. Ulaner G.A., Hoffman A.R., Otero J., Huang H.Y., Zhao Z., Mazumdar M., et al. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes, Chromosomes Cancer 41 (2004) 155-162
54. Johnson J.E., Varkonyi R.J., Schwalm J., Cragle R., Klein-Szanto A., Patchefsky A., et al. Multiple mechanisms of telomere maintenance exist in liposarcomas. Clin Cancer Res 11 (2005) 5347-5355
55. Kumakura S.I., Tsutsui T.W., Yagisawa J., Barrett J.C., and Tsutsui T. Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells. Cancer Res 65 (2005) 2778-2786
56. Gan Y., Mo Y., Johnston J., Lu J., Wientjes M.G., and Au J.L.S. Telomere maintenance in telomerase-positive human ovarian SKOV-3 cells cannot be retarded by complete inhibition of telomerase. FEBS Lett 524 1-3 (2002) 10-14
57. Brachner A., Sasgary S., Pirker C., Rodgarkia C., Mikula M., Mikulits W., et al. Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT. Cancer Res 66 7 (2006) 3584-3592
58. Cerone M.A., Autexier C., Londono-Vallejo J.A., and Bacchetti S. A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. Oncogene 24 (2005) 7893-7901
59. Argilla D., Chin K., Singh M., Hodgson J.G., Bosenberg M., Ortiz de Solorzano C., et al. Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes. Cancer Cell 6 4 (2004) 373-385
60. Marciniak R.A., Cavazos D., Montellano R., Chen Q., Guarente L., and Johnson F.B. A novel telomere structure in a human alternative lengthening of telomeres cell line. Cancer Res 65 (2005) 2730-2737
61. Tsai H.J., Huang W.H., Li T.K., Tsai Y.L., Wu K.J., Tseng S.F., et al. Involvement of topoisomerase III in telomere-telomere recombination. J Biol Chem 281 19 (2006) 13717-13723
62. Silverman J., Takai H., Buonomo S.B.C., Eisenhaber F., and de Lange T. Human Rif1, ortholog of a yeast telomeric protein, is regulated by ATM and 53BP1 and functions in the S-phase checkpoint. Genes Develop 18 (2004) 2108-2119
63. Jiang W.Q., Zhong Z.H., Henson J.D., Neumann A.A., Chang A.C.M., and Reddel R.R. Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol Cell Biol 25 7 (2005) 2708-2721